Breast Cancer Foundation NZ
Neo-N (Cohort C)
Early Breast Cancer clinical trials for Triple negative
The Neo-N clinical trial (Cohort C) aims to find out if two immunotherapy drugs called nivolumab and relatlimab work better together to help patients with triple negative breast cancer.
The original Neo-N trial looked at whether a new drug called nivolumab helps control breast cancer when added to standard chemotherapy and found that 50% of patients on the trial had no evidence of breast cancer following treatment. You can read about a patient's personal experience in this trial here.
Researchers are building on this finding with the Neo-N Cohort C trial, which will investigate if adding a new drug, relatlimab, given together with nivolumab, can further control breast cancer when added to standard chemotherapy for triple-negative breast cancer patients.
Both nivolumab and relatlimab are a type of drug called an "immune checkpoint inhibitor". They work by helping the body's immune system to fight cancer cells.
This study might be right for you if you have been newly diagnosed with early-stage triple negative breast cancer.
The Neo-N (cohort C) clinical trial will involve 16 sites in Australia and New Zealand and will enroll up to 54 patients in the study.
New Zealand
Australia
QLD
SA
VIC
WA
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Early Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.